Toronto-Dominion Bank vs Zimmer Biomet Holdings Inc — how do they compare? Toronto-Dominion Bank trades at $120.27 (market cap $197.03B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Toronto-Dominion Bank is far larger — about 11.3× Zimmer Biomet Holdings Inc's market cap, and Toronto-Dominion Bank pays the higher dividend (2.62%). Which is the better fit depends on your goals.
| TD | ZBH | |
|---|---|---|
Market Cap | $197.03B | $17.36B |
Sector | Financials | Health |
52-Week High | $124.80 | $107.71 |
52-Week Low | $72.55 | $79.58 |
Dividend Yield | 2.62% | 1.07% |
Enterprise Value | — | $24.40B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Trailing returns across standard periods
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →